Although the treatment of AML patients has changed little until recently [31], the AMLSG09-09 clinical trial showed that the addition of GO can extend relapse-free survival to a clinically relevant extent in CD33+ AML NPM1mut patients who achieve a CR [36,68]. This evidence concerns the gene CD33 and acute myeloid leukemia.